Velcade gains mantle cell claim
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryMillenium Pharmaceutical's oncologic Velcade (bortezomib) is approved for mantle cell lymphoma (MCL) in patients who have received at least one prior therapy, the company announces Dec. 8. MCL is a relatively uncommon and aggressive subtype of non-Hodgkins lymphoma for which there is no cure in the relapsed or refractory setting. The condition has a U.S. prevalence of 10,000 patients. The approval was based on the company's Phase II PINNACLE trial, a single-arm, open-label study that enrolled 155 patients and showed an overall response rate of 31 percent. Velcade is currently the market leader in multiple myeloma for patients who have received one prior therapy. The drug is being codeveloped with Johnson & Johnson...
You may also be interested in...
Hours before the US FDA confirmed the first drug shortage due to active pharmaceutical ingredient constraints because of the coronavirus situation in China, generics industry leader Mylan came under pressure about the potential impact on its business.
Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.
Laparoscopic power morcellation to remove uterine fibroids should only be performed with the use of a compatible containment system, and only on women younger than 50, the US FDA said in a newly published safety communication and draft guidance document. See what the president of the gynecologic trade group AAGL, Jubilee Brown, said about it here.